Name: 글로벌 시장 동향
SKU: PH4702
Availability: InStock

보고서 요약(국문)

시장 개요
담낭암 치료 시장 규모는 2022년 7,950만 달러에 달했으며, 2030년까지 1억 2,140만 달러에 이를 것으로 예상되어 높은 성장세를 보일 전망입니다. 전 세계 담낭암 치료 시장은 2023년부터 2030년까지 연평균 5.5%의 성장률을 기록할 것으로 예상됩니다.
담낭암 치료 시장은 전체 종양학 치료제 시장의 한 부문으로, 담낭암 치료에 중점을 두고 있습니다. 여기에는 수술, 화학요법, 방사선 치료, 표적 치료, 면역요법 등 다양한 치료법이 포함됩니다.
새로운 치료 접근법과 치료 혁신이 등장함에 따라 시장은 지속적으로 발전하고 있습니다. 의료진, 연구자, 제약 회사 간의 지속적인 연구, 임상 시험 및 협력이 시장의 미래를 형성할 것으로 기대됩니다.

담낭암 치료 시장은 담낭암 발병률 증가, 치료 옵션에 대한 인식 제고, 치료 옵션 관련 연구 개발 증가, 유리한 의료비 상환 정책, 첨단 진단 시설 도입 확대, 기술 발전 등의 요인에 의해 성장하고 있습니다.

시장 동향
첨단 진단 시설 도입 증가
담낭암 치료에 첨단 진단 시설 도입이 증가함에 따라 시장 점유율이 확대될 것으로 예상됩니다. 첨단 진단 시설은 담낭암의 조기 발견, 정확한 진단 및 병기 결정에 중요한 역할을 합니다.
또한, 분자 검사 및 바이오마커 분석을 포함한 첨단 진단 기술은 담낭암 치료에서 맞춤형 의학적 접근 방식을 가능하게 합니다. 이러한 기술은 특정 유전자 변이, 바이오마커 또는 종양의 분자적 특성을 식별하여 표적 치료 및 맞춤형 치료 계획을 수립할 수 있도록 합니다. 예를 들어, 순환 miR-141은 담낭암의 진단, 예후 및 치료 표적에 대한 잠재적 바이오마커입니다.
치료 옵션 관련 연구 개발 증가
연구 개발 노력은 담낭암 치료 옵션을 발전시키는 데 매우 중요합니다. 현재 진행 중인 연구 활동은 담낭암의 근본적인 메커니즘을 이해하고, 새로운 치료 표적을 식별하며, 혁신적인 치료 접근법을 개발하는 데 중점을 두고 있습니다.
표적 치료법의 등장은 담낭암을 포함한 암 치료에 혁명을 일으켰습니다. 연구자들은 특정 분자 표적을 식별하고 이러한 표적을 선택적으로 억제하거나 파괴하는 약물을 개발하여 보다 효과적이고 독성이 적은 치료법을 제공하고 있습니다. 표적 치료법은 개별 환자의 분자적 특성에 맞춘 맞춤형 정밀 치료 옵션을 제공할 가능성을 제시합니다.
예를 들어, 2023년 3월, 공립 의과대학원인 PGIMER 찬디가르는 말기 담낭암 치료를 위해 비가역적 전기천공법 임상 시험을 시작했습니다. 이 시술은 고전압의 단시간 전기 펄스를 암 종양에 가하여 종양 세포를 파괴하고 치유를 유도하는 것입니다.
제한된 치료 옵션
다른 유형의 암과 비교했을 때, 담낭암은 특히 진행성 또는 전이성 사례의 경우 치료 옵션이 제한적입니다. 제한된 치료 옵션은 최적의 치료 결과를 얻지 못하거나 환자의 반응률이 낮아질 수 있습니다. 기존 치료법의 효과가 제한적이거나 환자가 내성을 보이는 경우, 의료진이 선택할 수 있는 치료 옵션이 제한되어 환자의 치료 결과와 만족도에 부정적인 영향을 미칠 수 있습니다.
담낭암은 다양한 아형과 분자적 특성을 가진 복잡한 질병입니다. 제한된 치료 옵션으로는 질병의 이질성을 충분히 해결하지 못하여 각 환자에게 맞춤형의 정확한 치료를 제공하기 어렵습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 담낭암 치료 시장을 포함한 의료 산업에 심각한 영향을 미쳤습니다. 전 세계 의료 시스템은 COVID-19 환자 관리로 인해 과부하 상태에 놓였습니다. 담낭암 수술을 포함한 비응급 시술은 많은 경우 연기되거나 취소되어 치료가 지연되거나 중단되었습니다. 이는 담낭암 환자의 적시 치료 시작에 영향을 미쳤습니다.
팬데믹으로 인해 COVID-19 전파 위험을 최소화하고 의료 자원을 최적화하기 위해 치료 접근 방식의 변화가 필요했습니다. 어떤 경우에는 수술적 치료가 전신 치료나 방사선 치료와 같은 다른 치료법으로 대체되거나 연기되었습니다. 이러한 변화는 담낭암 환자의 전반적인 관리 및 치료 결과에 영향을 미칠 수 있습니다.
러시아-우크라이나 분쟁 분석
러시아-우크라이나 분쟁은 담낭암 치료 시장에 상당한 영향을 미쳤습니다. 분쟁으로 인해 공급망이 교란되고 의약품, 수술 장비, 진단 도구 등 필수 의료 용품의 공급이 제한될 수 있습니다. 이러한 물품의 부족 또는 접근성 제한은 담낭암 환자에게 제공되는 치료의 질에 영향을 미쳐 최적의 치료 결과를 얻지 못하게 할 수 있습니다.
분쟁 상황은 의료 전문가의 이주 또는 실향을 초래하여 의료 시스템에 더 큰 부담을 줄 수 있습니다. 숙련된 의료 인력의 손실은 담낭암 환자에게 적절하고 전문적인 치료를 제공할 수 있는 역량에 영향을 미칠 수 있습니다. 또한, 의료 종사자들은 분쟁 기간 동안 의학 교육 및 훈련 기회에 접근하는 데 어려움을 겪을 수 있으며, 이는 최신 의료 서비스를 제공하는 능력에 영향을 미칠 수 있습니다.
세분화 분석
글로벌 담낭암 치료 시장은 치료 방법, 적응증, 최종 사용자 및 지역별로 세분화됩니다.

치료 유형별로는 화학요법 부문이 시장 점유율을 주도할 것으로 예상됩니다.
화학요법은 2022년 전 세계 담낭암 치료 시장에서 38.2%의 점유율을 차지했습니다. 화학요법은 담낭암 치료에서 주요 치료법이자 복합 치료의 일환으로 중요한 역할을 합니다.
수술적 치료가 제한적인 진행성 또는 전이성 담낭암의 경우, 화학요법은 증상 완화, 생존 기간 연장, 환자의 삶의 질 향상을 위한 완화 치료로 사용됩니다. 완화 화학요법은 종양 크기를 줄이고, 통증을 완화하며, 기타 암 관련 증상을 관리하여 환자에게 안정을 제공합니다.
예를 들어, 게놈앤컴퍼니(Genome & Company)는 2023년 5월에 담도암 치료 후보 물질인 GEN-001 개발 전략을 수정할 예정입니다. 이 회사는 암의 이차 치료 동향을 분석하여 세포독성 화학요법과의 병용 투여 효과를 확인할 계획입니다. 해당 회사는 GEN-001의 국내 2상 임상시험을 위한 임상시험계획(IND) 변경 신청서를 식품의약품안전처에 제출했습니다.
지역 분석
북미, 높은 질병 부담과 선진 진단 시설로 최대 시장 점유율 차지
북미는 높은 질병 부담과 선진 진단 시설 덕분에 2022년 담낭암 치료 시장에서 41.2%의 시장 점유율을 차지했습니다. 북미는 다른 지역에 비해 담낭암 발병률이 상대적으로 높습니다. 생활 습관, 비만율, 유전적 소인 등의 요인이 이 지역의 높은 질병 부담에 기여하는 것으로 보입니다. 환자 수가 많다는 것은 담낭암 치료에 대한 수요가 많다는 것을 의미하며, 이는 시장 점유율 확대로 이어집니다.
북미는 선진 의료 인프라와 진단 역량으로 잘 알려져 있습니다. 이 지역에는 담낭암의 조기 발견 및 정확한 진단을 위한 최첨단 기술을 갖춘 병원, 클리닉, 영상 진단 센터 등 의료 시설이 잘 구축되어 있습니다. 조기 발견은 시기적절한 치료 시작을 가능하게 하고 환자의 치료 결과를 개선합니다.
경쟁 환경
시장의 주요 글로벌 업체로는 Eli Lilly and Company, Bristol-Myers Squibb Company, Cipla Inc, Pfizer Inc, F. Hoffmann–La Roche Ltd, Sanofi Inc, OncoTherapy Science Inc, Intuitive Surgical Inc, GLS Pharma Ltd, Sun Pharmaceutical Industries Ltd 등이 있습니다.
보고서 구매 이유

• 치료법, 적응증, 최종 사용자 및 지역별 글로벌 담낭암 치료 시장 세분화를 시각화하고 주요 상업적 자산과 업체를 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 다양한 담낭암 치료 시장 관련 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석을 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 Excel 파일을 제공합니다.

글로벌 담낭암 치료 시장 보고서는 약 54개의 표, 46개의 그림, 그리고 195페이지 분량으로 구성될 예정입니다.
주요 대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Gall Bladder Cancer Treatment Market size reached US$ 79.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$121.4 million by 2030. The Global Gall Bladder Cancer Treatment Market is exhibiting at a CAGR of 5.5% during the forecast period 2023-2030.
The Gall Bladder Cancer Treatment Market is a segment of the overall oncology therapeutics market, focusing on treating gallbladder cancer. It involves various modalities such as surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy.
The market continues to evolve as new treatment approaches and therapeutic innovations emerge. Ongoing research, clinical trials, and collaborations among healthcare providers, researchers, and pharmaceutical companies are expected to shape the market’s future.
The gall bladder cancer treatment market is driven by factors such as the increasing prevalence of gall bladder cancer, increasing awareness of treatment options, increasing research and developments in treatment options, favorable reimbursement policies, increasing adoption of advanced diagnostic facilities, and technological advancements.
Market Dynamics
Increasing Adoption of Advanced Diagnostic Facilities
The increasing adoption of advanced diagnostic facilities for gall bladder cancer treatment is expected to drive the market share. Advanced diagnostic facilities play a crucial role in the early detection, accurate diagnosis, and staging of gallbladder cancer.
Furthermore, advanced diagnostic techniques, including molecular testing and biomarker analysis, contribute to personalized medicine approaches in gallbladder cancer treatment. These techniques help identify specific genetic mutations, biomarkers, or molecular characteristics of the tumor, enabling targeted therapies and tailored treatment plans. For instance, Circulating miR-141 as a potential biomarker for diagnosis, prognosis, and therapeutic targets in gallbladder cancer.
Increasing Research and Developments in Treatment Options
Research and development efforts are vital in advancing treatment options for gallbladder cancer. Ongoing research activities focus on understanding the underlying mechanisms of gallbladder cancer, identifying new therapeutic targets, and developing innovative treatment approaches.
The emergence of targeted therapies has revolutionized cancer treatment, including gallbladder cancer. Researchers are identifying specific molecular targets and developing drugs that selectively inhibit or disrupt these targets, leading to more effective and less toxic treatments. Targeted therapies offer the potential for personalized and precise treatment options tailored to individual patients' molecular characteristics.
For instance, in March 2023, PGIMER Chandigarh, a public postgraduate medical research university started trials of irreversible electroporation for the treatment of late-stage gallbladder cancer through the procedure, the cancer tumor is given short-term electric pulses with high voltage to break tumor cells; allowing healing.
Limited Treatment Options
Compared to other types of cancer, gallbladder cancer has limited treatment options, especially for advanced or metastatic cases. Limited treatment options may lead to suboptimal treatment outcomes and lower patient response rates. If existing treatments have limited efficacy or patients develop resistt can restrict the options available to healthcare providers, potentially impacting patient outcomes and satisfaction.
Gallbladder cancer is a complex disease with various subtypes and molecular characteristics. Limited treatment options may not adequately address the heterogeneity of the disease, making it challenging to provide personalized and precise treatment approaches for each patient.
COVID-19 Impact Analysis
The COVID-19 pandemic profoundly impacted the healthcare industry, including the gallbladder cancer treatment market. Healthcare systems around the world have been overwhelmed with the management of COVID-19 patients. Non-urgent procedures, including surgeries for gallbladder cancer, have been postponed or canceled in many cases, leading to treatment delays and interruptions. This has affected the timely initiation of treatment for patients with gallbladder cancer.
The pandemic has necessitated changes in treatment approaches to minimize the risk of COVID-19 transmission and optimize healthcare resources. In some cases, surgical interventions may have been replaced or delayed by alternative treatment modalities such as systemic or radiation therapy. These changes may impact the overall management and outcomes of gallbladder cancer patients.
Russia-Ukraine Conflict Analysis
The Russia-Ukraine conflict had a significant impact on the gallbladder cancer treatment market. The competition can disrupt supply chains and hinder the availability of essential medical supplies, including medications, surgical equipment, and diagnostic tools. Shortages or limited access to these supplies can impact the quality of care provided to gallbladder cancer patients, potentially leading to suboptimal treatment outcomes.
Conflict situations can lead to the migration or displacement of healthcare professionals, which can further strain the healthcare system. The loss of skilled medical personnel can impact the capacity to provide adequate and specialized care for gallbladder cancer patients. Additionally, healthcare workers may face challenges in accessing medical education and training opportunities during conflict, which can affect their ability to provide up-to-date care.
Segment Analysis
The Global Gall Bladder Cancer Treatment Market is segmented based on treatment, indication, end-user, and region.
Based on Treatment, the Chemotherapy Segment is Expected to Dominate the Market Share
The market for chemotherapy holds 38.2% of the global gallbladder cancer treatment market share in 2022. Chemotherapy plays an important role in treating gallbladder cancer, both as a primary treatment option and as part of a multimodal approach.
In cases of advanced or metastatic gallbladder cancer where curative surgical options are limited, chemotherapy serves as a palliative treatment to control symptoms, prolong survival, and enhance the quality of life for patients. Palliative chemotherapy can help shrink tumors, alleviate pain, and manage other cancer-related symptoms, offering relief to patients.
For instance, in May 2023, Genome & Company will revise its strategy in developing a biliary tract cancer treatment candidate, GEN-001. The company plans to confirm the treatment effect of its combined use with cytotoxic chemotherapies by reflecting on cancer’s secondary treatment trend. The company had submitted applications for changing its investigational new drug (IND) plan for the domestic phase 2 clinical trial of GEN-001 to the Ministry of Food and Drug Safety.
Geographical Analysis
North America Holds the Largest Market Share Due to the High Disease Burden and Advanced Diagnostic Facilities
North America holds the 41.2% market share for the Gall Bladder Cancer Treatment Market in 2022 due to the high disease burden and advanced diagnostic facilities. North America has reported a relatively higher incidence of gallbladder cancer than other parts of the world. Factors such as lifestyle, obesity rates, and genetic predisposition may contribute to the higher disease burden in this region. The larger patient population translates to a greater demand for gallbladder cancer treatment, leading to a larger market share.
North America is known for its advanced healthcare infrastructure and diagnostic capabilities. The region has well-established medical facilities, including hospitals, clinics, and imaging centers, equipped with state-of-the-art technologies for early detection and accurate diagnosis of gallbladder cancer. This early detection facilitates the timely initiation of treatment and improves patient outcomes.
Competitive Landscape
The major global players in the market include Eli Lilly and Company, Bristol-Myers Squibb Company, Cipla Inc, Pfizer Inc, F. Hoffmann–La Roche Ltd, Sanofi Inc, OncoTherapy Science Inc, Intuitive Surgical Inc, GLS Pharma Ltd, and Sun Pharmaceutical Industries Ltd.
Why Purchase the Report?
• To visualize the Global Gall Bladder Cancer Treatment Market segmentation based on treatment, indication, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous gall bladder cancer treatment market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The Global Gall Bladder Cancer Treatment Market Report Would Provide Approximately 54 Tables, 46 Figures And 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment
3.2. Snippet by Indication
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Adoption of Advanced Diagnostic Facilities
4.1.1.2. Increasing Research and Developments in Treatment Options
4.1.2. Restraints
4.1.2.1. Higher Risk of Adverse Effects
4.1.2.2. High Cost of Treatment
4.1.2.3. Limited Treatment Options
4.1.3. Opportunity
4.1.3.1. Technological advancements in treatment procedures
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Chemotherapy*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Immunotherapy
7.4. Radiation Therapy
7.5. Others
8. By Indication
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.1.2. Market Attractiveness Index, By Indication
8.2. Stage I*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Stage II
8.4. Stage III
8.5. Stage IV
9. By End-User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Gynecology Clinics
9.4. Academic Centers
9.5. Research Centers
9.6. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. The U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. The UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Eli Lilly and Company*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Bristol-Myers Squibb Company
12.3. Cipla Inc.
12.4. Pfizer Inc.
12.5. F. Hoffmann–La Roche Ltd.
12.6. Sanofi Inc.
12.7. OncoTherapy Science Inc.
12.8. Intuitive Surgical Inc.
12.9. GLS Pharma Ltd.
12.10. Sun Pharmaceutical Industries Ltd.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Eli Lilly and Company, 4.	Key Developments, Bristol-Myers Squibb Company, Cipla Inc., Pfizer Inc., F. Hoffmann–La Roche Ltd., Sanofi Inc., OncoTherapy Science Inc., Intuitive Surgical Inc., GLS Pharma Ltd., Sun Pharmaceutical Industries Ltd.

표 목록 (Tables)

List of Tables

Table 1 Global Gall Bladder Cancer Treatment Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Gall Bladder Cancer Treatment Market Value, By Indication, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Gall Bladder Cancer Treatment Market Value, By End-User, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Gall Bladder Cancer Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Gall Bladder Cancer Treatment Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Gall Bladder Cancer Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 7 Global Gall Bladder Cancer Treatment Market Value, By Indication, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Gall Bladder Cancer Treatment Market Value, By Indication, 2021-2030 (US$ Million)

Table 9 Global Gall Bladder Cancer Treatment Market Value, By End-User, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Gall Bladder Cancer Treatment Market Value, By End-User, 2021-2030 (US$ Million)

Table 11 Global Gall Bladder Cancer Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Gall Bladder Cancer Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Gall Bladder Cancer Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 14 North America Gall Bladder Cancer Treatment Market Value, By Indication, 2021-2030 (US$ Million)

Table 15 North America Gall Bladder Cancer Treatment Market Value, By End-User, 2021-2030 (US$ Million)

Table 16 North America Gall Bladder Cancer Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Gall Bladder Cancer Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 18 South America Gall Bladder Cancer Treatment Market Value, By Indication, 2021-2030 (US$ Million)

Table 19 South America Gall Bladder Cancer Treatment Market Value, By End-User, 2021-2030 (US$ Million)

Table 20 South America Gall Bladder Cancer Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Gall Bladder Cancer Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 22 Europe Gall Bladder Cancer Treatment Market Value, By Indication, 2021-2030 (US$ Million)

Table 23 Europe Gall Bladder Cancer Treatment Market Value, By End-User, 2021-2030 (US$ Million)

Table 24 Europe Gall Bladder Cancer Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Gall Bladder Cancer Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Gall Bladder Cancer Treatment Market Value, By Indication, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Gall Bladder Cancer Treatment Market Value, By End-User, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Gall Bladder Cancer Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Gall Bladder Cancer Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Gall Bladder Cancer Treatment Market Value, By Indication, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Gall Bladder Cancer Treatment Market Value, By End-User, 2021-2030 (US$ Million)

Table 32 Eli Lilly and Company: Overview

Table 33 Eli Lilly and Company: Product Portfolio

Table 34 Eli Lilly and Company: Key Developments

Table 35 Bristol-Myers Squibb Company: Overview

Table 36 Bristol-Myers Squibb Company: Product Portfolio

Table 37 Bristol-Myers Squibb Company: Key Developments

Table 38 Cipla Inc.: Overview

Table 39 Cipla Inc.: Product Portfolio

Table 40 Cipla Inc.: Key Developments

Table 41 Pfizer Inc.: Overview

Table 42 Pfizer Inc.: Product Portfolio

Table 43 Pfizer Inc.: Key Developments

Table 44 F. Hoffmann–La Roche Ltd.: Overview

Table 45 F. Hoffmann–La Roche Ltd.: Product Portfolio

Table 46 F. Hoffmann–La Roche Ltd.: Key Developments

Table 47 Sanofi Inc.: Overview

Table 48 Sanofi Inc.: Product Portfolio

Table 49 Sanofi Inc.: Key Developments

Table 50 OncoTherapy Science Inc.: Overview

Table 51 OncoTherapy Science Inc.: Product Portfolio

Table 52 OncoTherapy Science Inc.: Key Developments

Table 53 Intuitive Surgical Inc.: Overview

Table 54 Intuitive Surgical Inc.: Product Portfolio

Table 55 Intuitive Surgical Inc.: Key Developments

Table 56 GLS Pharma Ltd.: Overview

Table 57 GLS Pharma Ltd.: Product Portfolio

Table 58 GLS Pharma Ltd.: Key Developments

Table 59 Sun Pharmaceutical Industries Ltd.: Overview

Table 60 Sun Pharmaceutical Industries Ltd.: Product Portfolio

Table 61 Sun Pharmaceutical Industries Ltd.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Gall Bladder Cancer Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 3 Global Gall Bladder Cancer Treatment Market Share, By Indication, 2022 & 2030 (%)

Figure 4 Global Gall Bladder Cancer Treatment Market Share, By End-User, 2022 & 2030 (%)

Figure 5 Global Gall Bladder Cancer Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Gall Bladder Cancer Treatment Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 7 Chemotherapy Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 8 Immunotherapy Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Radiation Therapy Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Others Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Global Gall Bladder Cancer Treatment Market Y-o-Y Growth, By Indication, 2022-2030 (%)

Figure 12 Stage I Indication in Global Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 13 Stage II Indication in Global Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Stage III Indication in Global Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 15 Stage IV Indication in Global Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Global Gall Bladder Cancer Treatment Market Y-o-Y Growth, By End-User, 2022-2030 (%)

Figure 17 Hospital End-User in Global Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 18 Gynecology Clinics End-User in Global Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 Academic Centers End-User in Global Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Research Centers End-User in Global Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 21 Others End-User in Global Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 Global Gall Bladder Cancer Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 23 North America Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 Asia-Pacific Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 25 Europe Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 26 South America Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 27 Middle East and Africa Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 28 North America Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 29 North America Gall Bladder Cancer Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 30 North America Gall Bladder Cancer Treatment Market Share, By Indication, 2022 & 2030 (%)

Figure 31 North America Gall Bladder Cancer Treatment Market Share, By End-User, 2022 & 2030 (%)

Figure 32 North America Gall Bladder Cancer Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 33 South America Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 34 South America Gall Bladder Cancer Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 35 South America Gall Bladder Cancer Treatment Market Share, By Indication, 2022 & 2030 (%)

Figure 36 South America Gall Bladder Cancer Treatment Market Share, By End-User, 2022 & 2030 (%)

Figure 37 South America Gall Bladder Cancer Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 38 Europe Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 39 Europe Gall Bladder Cancer Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 40 Europe Gall Bladder Cancer Treatment Market Share, By Indication, 2022 & 2030 (%)

Figure 41 Europe Gall Bladder Cancer Treatment Market Share, By End-User, 2022 & 2030 (%)

Figure 42 Europe Gall Bladder Cancer Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 43 Asia-Pacific Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 44 Asia-Pacific Gall Bladder Cancer Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 45 Asia-Pacific Gall Bladder Cancer Treatment Market Share, By Indication, 2022 & 2030 (%)

Figure 46 Asia-Pacific Gall Bladder Cancer Treatment Market Share, By End-User, 2022 & 2030 (%)

Figure 47 Asia-Pacific Gall Bladder Cancer Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 48 Middle East & Africa Gall Bladder Cancer Treatment Market Value, 2021-2030 (US$ Million)

Figure 49 Middle East & Africa Gall Bladder Cancer Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 50 Middle East & Africa Gall Bladder Cancer Treatment Market Share, By Indication, 2022 & 2030 (%)

Figure 51 Middle East & Africa Gall Bladder Cancer Treatment Market Share, By End-User, 2022 & 2030 (%)

Figure 52 Eli Lilly and Company: Financials

Figure 53 Bristol-Myers Squibb Company: Financials

Figure 54 Cipla Inc.: Financials

Figure 55 Pfizer Inc.: Financials

Figure 56 F. Hoffmann–La Roche Ltd.: Financials

Figure 57 Sanofi Inc.: Financials

Figure 58 OncoTherapy Science Inc.: Financials

Figure 59 Intuitive Surgical Inc.: Financials

Figure 60 GLS Pharma Ltd.: Financials

Figure 61 Sun Pharmaceutical Industries Ltd.: Financials

세계 담낭암 치료 시장 – 2023-2030

Global Gall Bladder Cancer Treatment Market - 2023-2030